# Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux

> **NCT00369265** · PHASE4 · TERMINATED · sponsor: **American Institute for Voice and Ear Research** · enrollment: 18 (actual)

## Conditions studied

- Laryngopharyngeal Reflux

## Interventions

- **DRUG:** Lansoprazole
- **DIETARY_SUPPLEMENT:** Sugar pill

## Key facts

- **NCT ID:** NCT00369265
- **Lead sponsor:** American Institute for Voice and Ear Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Pharmaceutical company purchased by another company and funding was terminated.
- **Last updated:** 2012-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369265, "Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00369265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*